N. Duployez, C. Willekens, A. Marceau-renaut, E. Boudry-labis, and C. Preudhomme, Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors, Expert Review of Hematology, vol.97, issue.13, pp.43-56, 2015.
DOI : 10.1073/pnas.97.13.7521

J. Downing, The core-binding factor leukemias: lessons learned from murine models, Current Opinion in Genetics & Development, vol.13, issue.1, pp.48-54, 2003.
DOI : 10.1016/S0959-437X(02)00018-7

J. Wiemels, Z. Xiao, P. Buffler, A. Maia, X. Ma et al., AML1-ETO translocations in childhood acute myeloid leukemia, In utero origin of t Blood, vol.21, issue.99, pp.3801-3806, 2002.

T. Miyamoto, K. Nagafuji, K. Akashi, M. Harada, T. Kyo et al., Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia, Blood, vol.87, pp.4789-96, 1996.

E. Jourdan, N. Boissel, S. Chevret, E. Delabesse, A. Renneville et al., Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, vol.121, issue.12
DOI : 10.1182/blood-2012-10-462879

, Blood, vol.121, pp.2213-2236, 2013.

N. Duployez, A. Marceau-renaut, N. Boissel, A. Petit, M. Bucci et al., Comprehensive mutational profiling of core binding factor acute myeloid leukemia, Blood, vol.127, issue.20, pp.2451-2460, 2016.
DOI : 10.1182/blood-2015-12-688705

Z. Faber, X. Chen, A. Gedman, K. Boggs, J. Cheng et al., The genomic landscape of core-binding factor acute myeloid leukemias, Nature Genetics, vol.511, issue.12, pp.1551-1557, 2016.
DOI : 10.1016/j.celrep.2012.12.008

URL : http://europepmc.org/articles/pmc5508996?pdf=render

R. Schlenk, A. Benner, J. Krauter, T. Büchner, C. Sauerland et al., Individual Patient Data???Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup, Journal of Clinical Oncology, vol.22, issue.18, pp.3741-50, 2004.
DOI : 10.1200/JCO.2004.03.012

G. Marcucci, K. Mrózek, A. Ruppert, K. Maharry, J. Kolitz et al., Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.23, issue.24, pp.5705-5722, 2005.
DOI : 10.1200/JCO.2005.15.610

F. Appelbaum, K. Kopecky, M. Tallman, M. Slovak, H. Gundacker et al., The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations, British Journal of Haematology, vol.88, issue.2, pp.165-73, 2006.
DOI : 10.1038/nrc840

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06276.x/pdf

J. Cazier, C. Holmes, J. Broxholme, and . Greve, GREVE: Genomic Recurrent Event ViEwer to assist the identification of patterns across individual cancer samples, Bioinformatics, vol.102, issue.6, pp.2981-2983, 2012.
DOI : 10.1038/sj.bjc.6605589

URL : https://academic.oup.com/bioinformatics/article-pdf/28/22/2981/662324/bts547.pdf

D. Sweetser, A. Peniket, C. Haaland, A. Blomberg, Y. Zhang et al., Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia, Genes, Chromosomes and Cancer, vol.98, issue.3, pp.279-91, 2005.
DOI : 10.3109/10428199809092683

F. Dayyani, J. Wang, J. Yeh, E. Ahn, T. E. Zhang et al., Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival, Blood, vol.111, issue.8, pp.4338-4385, 2008.
DOI : 10.1182/blood-2007-07-103291

M. Mikulasovich, A. Leblanc, A. Scalise, D. Manwani, A. Keyzner et al., Duplication and triplication of der(21)t(8;21)(q22;q22) in acute myeloid leukemia, Cancer Genetics and Cytogenetics, vol.188, issue.2
DOI : 10.1016/j.cancergencyto.2008.10.004

, Cancer Genet Cytogenet, vol.188, pp.83-90, 2009.

X. Wang, H. Dai, Q. Wang, Q. Wang, Y. Xu et al., EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia, PLoS ONE, vol.18, issue.4, p.61341, 2013.
DOI : 10.1371/journal.pone.0061341.s002

C. Chen, Y. Liu, A. Rappaport, T. Kitzing, N. Schultz et al., MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia, Cancer Cell, vol.25, issue.5, pp.652-65, 2014.
DOI : 10.1016/j.ccr.2014.03.016

M. Kühn, I. Radtke, L. Bullinger, S. Goorha, J. Cheng et al., High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations, Blood, vol.119, issue.10, pp.67-75, 2012.
DOI : 10.1182/blood-2011-09-380444

T. Hirano, R. Yoshikawa, H. Harada, Y. Harada, A. Ishida et al., Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression, Molecular Cancer, vol.288, issue.1, pp.90-12943, 2015.
DOI : 10.1006/bbrc.2001.5798

J. Grönholm, M. Kaustio, H. Myllymäki, J. Kallio, J. Saarikettu et al., Not4 enhances JAK/STAT pathway-dependent gene expression in Drosophila and in human cells, The FASEB Journal, vol.118, issue.3, pp.1239-50, 2012.
DOI : 10.1042/BJ20090500

L. Hartmann, S. Dutta, S. Opatz, S. Vosberg, K. Reiter et al., ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation, Nature Communications, vol.31, p.11733, 2016.
DOI : 10.1093/bioinformatics/btv362

V. Lavallée, S. Lemieux, G. Boucher, P. Gendron, I. Boivin et al., RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature, Blood, vol.127, issue.20, pp.2498-501, 2016.
DOI : 10.1182/blood-2016-03-703868

I. Radtke, C. Mullighan, M. Ishii, X. Su, J. Cheng et al., Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia, Proceedings of the National Academy of Sciences, vol.456, issue.7218, pp.12944-12949, 2009.
DOI : 10.1038/nature07485

A. Renneville, R. Abdelali, S. Chevret, O. Nibourel, M. Cheok et al., Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia, Oncotarget. Leukemia, vol.5, issue.31, pp.916-948, 2013.

M. Krauth, C. Eder, T. Alpermann, U. Bacher, N. Nadarajah et al., High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome, Leukemia, vol.102, issue.7, pp.1449-58, 2014.
DOI : 10.1182/blood-2002-11-3527

P. Paschka, J. Du, R. Schlenk, V. Gaidzik, L. Bullinger et al., Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG), Blood, vol.121, issue.1, pp.170-177, 2013.
DOI : 10.1182/blood-2012-05-431486

J. Micol, N. Duployez, N. Boissel, A. Petit, S. Geffroy et al., Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations, Blood, vol.124, issue.9, pp.1445-1454, 2014.
DOI : 10.1182/blood-2014-04-571018

URL : http://www.bloodjournal.org/content/bloodjournal/124/9/1445.full.pdf

M. Katoh, M. Igarashi, H. Fukuda, H. Nakagama, and M. Katoh, Cancer genetics and genomics of human FOX family genes, Cancer Letters, vol.328, issue.2
DOI : 10.1016/j.canlet.2012.09.017

, Cancer Lett, vol.328, pp.198-206, 2013.

T. Klampfl, A. Harutyunyan, T. Berg, B. Gisslinger, M. Schalling et al., Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression, Blood, vol.118, issue.1, pp.167-76, 2011.
DOI : 10.1182/blood-2011-01-331678

L. Bullinger, J. Krönke, V. Gaidzik, H. Döhner, and K. Döhner, Comment on ???Integrative genomic profiling of human prostate cancer???, Leukemia, vol.24, issue.11, pp.1970-1972, 2010.
DOI : 10.1261/rna.1532109

J. Milosevic, A. Puda, L. Malcovati, T. Berg, M. Hofbauer et al., Clinical significance of genetic aberrations in secondary acute myeloid leukemia, American Journal of Hematology, vol.112, issue.11, pp.1010-1016, 2012.
DOI : 10.1046/j.1365-2141.2001.02511.x

C. Shi, M. Sakuma, T. Mooroka, A. Liscoe, H. Gao et al.,

, Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function, Blood, vol.112, pp.4699-711, 2008.

X. Liu, Z. Liu, C. Gerarduzzi, D. Choi, S. Ganapathy et al., Somatic human ZBTB7A zinc finger mutations promote cancer progression, Oncogene, vol.464, issue.23, pp.3071-3079, 2016.
DOI : 10.1038/nprot.2006.27

T. Hirano, Is CCDC26 a Novel Cancer-Associated Long- Chain Non-Coding RNA? Oncogene and Cancer -From Bench to Clinic, pp.415-449, 2013.

S. Shete, F. Hosking, L. Robertson, S. Dobbins, M. Sanson et al., Genome-wide association study identifies five susceptibility loci for glioma, Nature Genetics, vol.16, issue.8, pp.899-904, 2009.
DOI : 10.1038/nmeth.1282

W. Peng and A. Jiang, Long noncoding RNA CCDC26 as a potential predictor biomarker contributes to tumorigenesis in pancreatic cancer, Biomedicine & Pharmacotherapy, vol.83, pp.712-719, 2016.
DOI : 10.1016/j.biopha.2016.06.059

W. Yin, A. Rossin, J. Clifford, and H. Gronemeyer, Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM, Oncogene, vol.25, issue.26, pp.3735-3779, 2006.
DOI : 10.1074/jbc.274.17.11549

URL : https://hal.archives-ouvertes.fr/hal-00188233

T. Hirano, The role of the CCDC26 long noncoding RNA as a tumor suppressor, RNA Dis, 2015.

R. Tiu, L. Gondek, O. Keefe, C. Huh, J. Sekeres et al., New Lesions Detected by Single Nucleotide Polymorphism Array???Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.27, issue.31, pp.5219-5245, 2009.
DOI : 10.1200/JCO.2009.21.9840

O. Keefe, C. Mcdevitt, M. Maciejewski, and J. , Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies, Blood, vol.115, issue.14, pp.2731-2740, 2009.
DOI : 10.1182/blood-2009-10-201848

S. Heinrichs, C. Li, and A. Look, SNP array analysis in hematologic malignancies: avoiding false discoveries, Blood, vol.115, issue.21, pp.4157-61, 2009.
DOI : 10.1182/blood-2009-11-203182